| Danielle Nicole Wills, OTR | |
|
3600 W Bethel Ave, Muncie, IN 47304-5407 | |
| (800) 622-6575 | |
| Not Available |
| Full Name | Danielle Nicole Wills |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapy |
| Experience | 6 Years |
| Location | 3600 W Bethel Ave, Muncie, Indiana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003467903 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | 31006848A (Indiana) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Central Indiana Orthopedics Llc | 5698667822 | 142 |
News Archive
A minimally-invasive treatment just became available to men suffering from prostate cancer in the United States. After more than 10 years of clinical trials, the Food and Drug Administration on October 9 approved the use of High Intensity Focused Ultrasound (HIFU), a procedure that can zero in on cancer cells while protecting surrounding tissue and minimizing chances for erectile and urinary dysfunction associated with other treatments.
A drug-eluting coronary stent, or "scaffold" made from bioresorbable material, showed similar efficacy and safety results compared to a metal stent in patients undergoing percutaneous coronary intervention (PCI), according to results of the ABSORB Japan study.
The results of a study presented today at the Annual European Congress of Rheumatology report that obesity in women and current smoking in men were the strongest predictors of not achieving remission in early rheumatoid arthritis within a year.
Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Carbidopa and Levodopa Tablets USP, 10mg/100mg, 25mg/100mg and 25mg/250 mg.
› Verified 3 days ago
| Provider Name | Central Indiana Orthopedics Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1063422137 PECOS PAC ID: 5698667822 Enrollment ID: O20040325000156 |
News Archive
A minimally-invasive treatment just became available to men suffering from prostate cancer in the United States. After more than 10 years of clinical trials, the Food and Drug Administration on October 9 approved the use of High Intensity Focused Ultrasound (HIFU), a procedure that can zero in on cancer cells while protecting surrounding tissue and minimizing chances for erectile and urinary dysfunction associated with other treatments.
A drug-eluting coronary stent, or "scaffold" made from bioresorbable material, showed similar efficacy and safety results compared to a metal stent in patients undergoing percutaneous coronary intervention (PCI), according to results of the ABSORB Japan study.
The results of a study presented today at the Annual European Congress of Rheumatology report that obesity in women and current smoking in men were the strongest predictors of not achieving remission in early rheumatoid arthritis within a year.
Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Carbidopa and Levodopa Tablets USP, 10mg/100mg, 25mg/100mg and 25mg/250 mg.
› Verified 3 days ago
| Provider Name | Advanced Physical Therapy Llc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1316940505 PECOS PAC ID: 6002959525 Enrollment ID: O20111006000030 |
News Archive
A minimally-invasive treatment just became available to men suffering from prostate cancer in the United States. After more than 10 years of clinical trials, the Food and Drug Administration on October 9 approved the use of High Intensity Focused Ultrasound (HIFU), a procedure that can zero in on cancer cells while protecting surrounding tissue and minimizing chances for erectile and urinary dysfunction associated with other treatments.
A drug-eluting coronary stent, or "scaffold" made from bioresorbable material, showed similar efficacy and safety results compared to a metal stent in patients undergoing percutaneous coronary intervention (PCI), according to results of the ABSORB Japan study.
The results of a study presented today at the Annual European Congress of Rheumatology report that obesity in women and current smoking in men were the strongest predictors of not achieving remission in early rheumatoid arthritis within a year.
Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Carbidopa and Levodopa Tablets USP, 10mg/100mg, 25mg/100mg and 25mg/250 mg.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Danielle Nicole Wills, OTR 8312 S Canoe Trl, Pendleton, IN 46064-8578 Ph: (317) 201-6058 | Danielle Nicole Wills, OTR 3600 W Bethel Ave, Muncie, IN 47304-5407 Ph: (800) 622-6575 |
News Archive
A minimally-invasive treatment just became available to men suffering from prostate cancer in the United States. After more than 10 years of clinical trials, the Food and Drug Administration on October 9 approved the use of High Intensity Focused Ultrasound (HIFU), a procedure that can zero in on cancer cells while protecting surrounding tissue and minimizing chances for erectile and urinary dysfunction associated with other treatments.
A drug-eluting coronary stent, or "scaffold" made from bioresorbable material, showed similar efficacy and safety results compared to a metal stent in patients undergoing percutaneous coronary intervention (PCI), according to results of the ABSORB Japan study.
The results of a study presented today at the Annual European Congress of Rheumatology report that obesity in women and current smoking in men were the strongest predictors of not achieving remission in early rheumatoid arthritis within a year.
Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Carbidopa and Levodopa Tablets USP, 10mg/100mg, 25mg/100mg and 25mg/250 mg.
› Verified 3 days ago
Patrick Douglas Robbins, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 2401 W University Ave, Muncie, IN 47303 Phone: 765-747-3111 | |
Mr. Drew Slentz, OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3300 W Community Dr, Muncie, IN 47304 Phone: 765-751-2555 Fax: 765-751-2694 | |
Kristi M Dugan, OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 205 N Tillotson Ave, Muncie, IN 47304 Phone: 765-254-9735 Fax: 765-254-9739 | |
Kamna Agarwal, OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3600 W Bethel Ave, Muncie, IN 47304 Phone: 765-213-3870 Fax: 765-213-3888 | |
Rebecca C Williams, OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 2401 W University Ave, Muncie, IN 47303 Phone: 765-747-3656 | |
Kacey N Quaderer, OT Occupational Therapist Medicare: Medicare Enrolled Practice Location: 2401 W University Ave, Muncie, IN 47303 Phone: 765-747-3013 |